一项多中心前瞻性随机对照试验,比较微血尿患者的 Cxbladder 分诊与膀胱镜检查。无症状微血尿风险安全检测试验。

Yair Lotan, Siamak Daneshmand, Neal Shore, Peter Black, Kristen R Scarpato, Amit Patel, Tony Lough, Daniel A Shoskes, Jay D Raman
{"title":"一项多中心前瞻性随机对照试验,比较微血尿患者的 Cxbladder 分诊与膀胱镜检查。无症状微血尿风险安全检测试验。","authors":"Yair Lotan, Siamak Daneshmand, Neal Shore, Peter Black, Kristen R Scarpato, Amit Patel, Tony Lough, Daniel A Shoskes, Jay D Raman","doi":"10.1097/ju.0000000000003991","DOIUrl":null,"url":null,"abstract":"AUA guidelines for patients with microhematuria (≥3 red blood cells [RBC]/high-power field [hpf]) include cystoscopy for most over age 40 due to risk of urothelial cancer (UC). Cxbladder Triage (CxbT) is a urinary genomic test with UC negative predictive value of 99%. In this prospective randomized controlled trial, we compared cystoscopy use in a standard of care (SOC) arm vs a marker-based approach.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"140 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial.\",\"authors\":\"Yair Lotan, Siamak Daneshmand, Neal Shore, Peter Black, Kristen R Scarpato, Amit Patel, Tony Lough, Daniel A Shoskes, Jay D Raman\",\"doi\":\"10.1097/ju.0000000000003991\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"AUA guidelines for patients with microhematuria (≥3 red blood cells [RBC]/high-power field [hpf]) include cystoscopy for most over age 40 due to risk of urothelial cancer (UC). Cxbladder Triage (CxbT) is a urinary genomic test with UC negative predictive value of 99%. In this prospective randomized controlled trial, we compared cystoscopy use in a standard of care (SOC) arm vs a marker-based approach.\",\"PeriodicalId\":501636,\"journal\":{\"name\":\"The Journal of Urology\",\"volume\":\"140 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ju.0000000000003991\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ju.0000000000003991","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

针对微血尿(红细胞[RBC]≥3 个/高倍视野[hpf])患者的 AUA 指南包括,由于存在泌尿道癌(UC)风险,大多数 40 岁以上的患者都应接受膀胱镜检查。Cxbladder Triage(CxbT)是一种尿液基因组检验,其 UC 阴性预测值为 99%。在这项前瞻性随机对照试验中,我们比较了标准护理(SOC)组与基于标记物的方法中膀胱镜检查的使用情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
AUA guidelines for patients with microhematuria (≥3 red blood cells [RBC]/high-power field [hpf]) include cystoscopy for most over age 40 due to risk of urothelial cancer (UC). Cxbladder Triage (CxbT) is a urinary genomic test with UC negative predictive value of 99%. In this prospective randomized controlled trial, we compared cystoscopy use in a standard of care (SOC) arm vs a marker-based approach.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION). Reply: Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 COURAGE Trial. Reviewer of the Month: Geoffrey Sonn. Comparative Analysis of Holmium Laser Enucleation of the Prostate (HoLEP) and Robotic Assisted Simple Prostatectomy (RASP) in BPH Management: A Systematic Review and Meta-Analysis. Clinical Factors Associated with Suspicious 18F-DCFPyL PSMA PET Activity in Patients Initially Managed with Radical Prostatectomy including PSA <0.5 ng/mL.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1